Recruiting

Translumbosacral Neuromodulation

Sponsor:

Augusta University

Code:

NCT03899181

Conditions

Fecal Incontinence

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Translumbosacral Neuromodulation Therapy (TNT)

Sham TNT Therapy

Study Details

Brief summary:

Fecal Incontinence (FI) affects 40 million Americans, predominantly women and elderly. It is a major health care burden, significantly impairs quality of life and psychosocial function. FI is characterized by multifactorial dysfunction including lumbosacral neuropathy, anorectal sensori-motor dysfunction, and abnormal pelvic floor-brain innervation. A critical barrier to progress in the treatment of FI is the lack of RCTs, absence of mechanistically based non-invasive therapies that modify disease, and a lack of understanding on how treatments affect pathophysiology of FI. Consequently, most current remedies remain ineffective. Our long-term goal is to address the problem of lack of effective treatments for FI by investigating treatments that modulate neuronal perturbations and thereby improve sensory and motor control, and to understand the neurobiologic basis of these treatments. Our central hypothesis is that a novel, non-invasive treatment consisting of Translumbosacral Neuromodulation Therapy (TNT), using repetitive magnetic stimulation, will significantly improve FI in the short-term and long-term, by enhancing neural excitability and inducing neuroplasticity. Our approach is based on compelling pilot study which showed that TNT at 1 Hz frequency, significantly improved FI, by enhancing bidirectional gut- brain signaling, anal sphincter strength and rectal sensation compared to 5 or 15 Hz. Our objectives are to 1) investigate the efficacy, safety and optimal dose of a new treatment, TNT, in a sham controlled, randomized dose-dependent study in 132 FI patients; 2) determine the mechanistic basis for TNT by assessing the efferent and afferent pelvic floor-brain signaling, and sensori-motor function; 3) identify the durability of treatment response and effects of TNT, and whether reinforcement TNT provides augmented improvement, by performing a long-term, sham controlled randomized trial. Our expected outcomes include the demonstration of TNT as a durable, efficacious, safe, mechanistically based, non-invasive, and low risk treatment for FI. The impact of our project includes a novel, disease modifying, non-invasive treatment, a scientific basis for this treatment, and improved understanding of the pathophysiology of FI and how TNT modifies bidirectional gut and brain axes and anorectal function. Ultimately, the knowledge generated by this project will provide new avenues for the development of innovative, evidence-based therapies for FI.

Conditions

Fecal Incontinence

Study ID

NCT03899181

Start date

Jun 5, 2019

Status verified date

Jul, 2022

Completion date

Feb, 2025

Anticipated

Primary completion date

Feb, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Recurrent episodes of FI for 6 months;
  • No mucosal disease (colonoscopy + biopsy); and
  • On a 2-week stool diary patients reported at least one episode of solid or liquid FI/week.

Exclusion Criteria:

  • severe diarrhea (>6 liquid stools/day, Bristol scale >6);
  • on opioids,);
  • active depression;
  • severe cardiac disease, chronic renal failure or previous GI surgery except cholecystectomy and appendectomy;
  • neurologic diseases (e.g. head injury, epilepsy, multiple sclerosis, strokes, spinal cord injury) and increased intracranial pressure;
  • metal implants (within 30 cm of magnetic coil placement), pacemakers;
  • previous pelvic surgery/radiation, radical hysterectomy;
  • Ulcerative and Crohn's colitis;
  • rectal prolapse;
  • active anal fissure, anal abscess, congenital anorectal malformation, fistulae or inflamed hemorrhoids;
  • pregnant women

Study Design

Enrollment

132 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: 1 Hz 2400 TNT Treatment

Intervention: TNT treatment intervention with 2400 total stimulations with the magnetic coil..

active comparator: 1 Hz 3600 TNT Treatment

Intervention: TNT treatment intervention with 3600 total stimulations with the magnetic coil.

sham comparator: Sham TNT Treatment

This arm will have the sham treatment session. First we will assess the motor threshold intensity described above. Next, a sham coil is placed on each of 4 regions (2 lumbar \& 2 sacral), and 600 stimulations will be given at each site in 2 trains, with a 5 minutes rest period between each site and 3 minutes between trains.

Interventions

Translumbosacral Neuromodulation Therapy (TNT)

A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.

Sham TNT Therapy

This is the sham TNT treatment as mentioned in the different ARMs using the fake coil with no magnetic stimulations.

Primary outcome measure

  • AIM 1 Primary Outcome measure is the proportion of patients achieving >50% of reduction in fecal incontinence episodes/weeks at the end of 6 weeks compared to baseline. [ Time Frame: 6 weeks (short term) ]
  • AIM 2: Latencies for lumbo-anal Magnetic Evoked Potentials (MEP) responses compared to baseline [ Time Frame: 6 weeks ]
  • AIM 2: Latencies for sacro-anal MEP responses compared to baseline [ Time Frame: 6 weeks ]
  • AIM 2: Latencies for the ano-cortical Cortical Evoked Potentials (CEP) responsecompared to baseline. [ Time Frame: 6 weeks ]
  • AIM 3:Primary Outcome measure is the proportion of patients achieving >50% of reduction in fecal incontinence episodes/weeks at the end of 48 weeks compared to baseline. [ Time Frame: 48 weeks (long term) ]
  • AIM 3: Latencies for lumbo-anal MEP responses [ Time Frame: 48 weeks ]
  • AIM 3: Latencies for sacro-anal MEP responses [ Time Frame: 48 weeks ]
  • AIM 3: Latencies for the ano-cortical CEP response . [ Time Frame: 48 weeks ]

Central Contacts and Locations

Central contacts

Satish Rao, MD, PhD

7067212238srao@augusta.edu

Locations

Augusta University

Recruiting

Augusta, Georgia, United States, 30912-4810

Contacts

Tennekoon Karunaratne, MD,PhD

+1-706-721-1968tkarunaratne@augusta.edu

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114-2621

Contacts

Principal Investigator:

Braden Kuo, MD

More Information

Sponsor

Augusta University

Last update posted

Jul 21, 2022

Last verified

Jul, 2022

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Augusta University on 2022-07-21.